From The Economist's newsfeed.
"Moderna and Merck, two American pharma companies, reported successful interim results in the trial of a personalised skin-cancer vaccine. The combination of an mRNA jab with an immunotherapy drug already produced by Merck reduced melanoma recurrence. The positive results are the first for a late-stage trial of an mRNA cancer vaccine. Both companies’ share prices rose; Moderna’s surged by 177%."
From AI: "The Trump administration has indeed moved to wind down or cancel major federal support for mRNA research, especially through HHS and BARDA, beginning in 2025. The key action is the cancellation of 22 federally funded mRNA vaccine development projects—roughly $500 million in research—along with earlier cancellations of large Moderna contracts."